Clinical Report: EGRG-Based Prognostic Signature in Lung Adenocarcinoma

Overview

A 17-gene prognostic signature related to endoplasmic reticulum stress and Golgi apparatus dysfunction was developed for lung adenocarcinoma (LUAD).

Background

Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer, presenting significant clinical challenges due to its heterogeneity and resistance to therapies. Understanding the molecular mechanisms underlying LUAD progression, particularly those involving endoplasmic reticulum stress and Golgi apparatus dysfunction, is crucial.

Data Highlights

Key Findings

• A 17-gene prognostic signature was established based on endoplasmic reticulum stress and Golgi apparatus-related genes.
• The signature was validated in independent LUAD cohorts, demonstrating prognostic utility.
• Patients were categorized into risk groups with significant differences in immune microenvironment characteristics.
• MUC16 was identified as a key gene, with increased expression linked to worse patient outcomes.
• Functional studies suggest MUC16 facilitates malignant phenotypes via FAK-mediated PI3K/AKT signaling activation.

Clinical Implications

The EGRG-based prognostic signature may assist in risk stratification for LUAD patients. MUC16's role in LUAD progression highlights its potential as a prognostic biomarker.

Conclusion

An EGRG-based prognostic signature for LUAD has been established.

Related Resources & Content

1. Journal of Crohn's and Colitis, 2026 -- Susceptibility to inflammatory bowel diseases promotes invasive carcinomas in a murine model of ATF6-driven colon cancer
2. Frontiers in Oncology, 2026 -- GLIS3 drives epithelial–mesenchymal transition and cancer stem–like traits in stomach adenocarcinoma via TGFBR3–Hedgehog signaling
3. MDSpire News, 2026 -- PRKG2: Genetic Link Between SSc and LUAD
4. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline | ASCO Publications
5. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study | Journal of Clinical Oncology
6. Frontiers in Immunology — Exploring the Multifaceted Functions of the mTOR-Glycolytic Pathway in Ulcerative Colitis: Implications for Immunometabolic Imbalance and Mucosal Barrier Alterations
7. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline | ASCO Publications
8. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study | Journal of Clinical Oncology
9. Endoplasmic reticulum stress responses in anticancer immunity | Nature Reviews Cancer